In todays NYT, a very interesting article highlighting the sort of deals/partnerships that are possible with big pharma from the results of small, early stage trials, that show 'impressive' results.
In this case, in a trial of only 10 patients, who had severe heart desease, where previous treatments had failed to reduce their cholesterol , they were treated with an experimental cholesterol-lowering treatment using gene editing. Researchers reported that 'the treatment appeared to reduce cholesterol levels markedly in patients and that it appeared to be safe'.
Eli Lilly have paid $60 million to to collaborate with Verve Therapeutics and opted to acquire additional rights to Verve’s programs for an additional $250 million. If the editing continues to look promising, Eli Lilly expects to help with larger studies.
https://1ft.io/proxy?q=https%3A%2F%2Fwww.nytimes.com%2F2023%2F11%2F12%2Fhealth%2Fcholesterol-gene-editing-study.html
AML partnership anyone ??
Industry news, page-1493
-
- There are more pages in this discussion • 325 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.86 |
Change
-0.015(0.80%) |
Mkt cap ! $316.8M | |||
| Open | High | Low | Value | Volume |
| $1.88 | $1.88 | $1.79 | $163.0K | 89.00K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34299 | $1.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.86 | 3635 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |